Search | Page 11 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. An update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromes.

    ... prognosis. The mainstay of treatment includes cytoxic chemotherapy and supportive care . Over the last decade, promising ...

    Research Article last updated 10/11/2011 - 5:58pm.

  2. The epidemiology of myelodysplastic syndromes.

    ... include advanced age, male gender, previous exposure to chemotherapy or radiation therapy, smoking, or, in rare cases, exposure to ...

    Research Article last updated 10/11/2011 - 5:58pm.

  3. Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C.

    ... cytarabine (LDara-C), the most widely used low-dose chemotherapy in patients with higher-risk myelodysplastic syndrome (MDS) ...

    Research Article last updated 10/11/2011 - 5:58pm.

  4. Enhancing survival outcomes in the management of patients with higher-risk myelodysplastic syndromes.

    ... therapies include cytarabine-based remission induction chemotherapy and hematopoietic stem cell transplantation. Transplantation ...

    Research Article last updated 10/11/2011 - 5:58pm.

  5. Impact on survival of different treatments for myelodysplastic syndromes (MDS).

    ... low-dose Ara-C, antithymocyte globulin (ATG), induction chemotherapy , or allogeneic stem cell transplantation (allo-SCT). For all ...

    Research Article last updated 10/11/2011 - 5:58pm.

  6. Azacitidine adverse effects in patients with myelodysplastic syndromes

    ... syndromes who are not candidates for high-dose chemotherapy . Considering the mechanism of action of the agent, it is ...

    Research Article last updated 10/11/2011 - 5:58pm.

  7. Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine*.

    ... (CCR), which included low-dose ara-C, BSC, or intensive chemotherapy . In both studies, azacitidine dose was 75 mg/m(2)/d SC for 7 ...

    Research Article last updated 10/11/2011 - 5:58pm.

  8. Microtransplantation to Treat Refractory or Relapsed Hematologic Malignancies in Younger Patients

    ... transplant, patients receive very high doses of chemotherapy and/or radiation therapy, followed by an infusion of their ... bone marrow or blood stem cells . The high-dose chemotherapy drugs and radiation are given to remove the leukemia cells in the ...

    Clinical Trial last updated 05/09/2016 - 3:01pm.

  9. Myelodysplastic syndromes: 2012 update on diagnosis, risk-stratification, and management

    ... lenalidomide , hypomethylating agents, intensive chemotherapy , and allogeneic stem cell transplantation. The use of ...

    Research Article last updated 07/31/2012 - 2:02pm.

  10. Myelodysplastic syndromes: 2011 update on diagnosis, risk-stratification, and management

    ... lenalidomide , hypomethylating agents, intensive chemotherapy , and allogeneic stem cell transplantation. The use of ...

    Research Article last updated 10/11/2011 - 5:58pm.